Recent Updates
Recently added Catalysts
AMPH Positive Sentiment

Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference

Key Takeaway: Amphastar Pharmaceuticals will participate in the 20th Annual Needham Virtual Healthcare Conference, featuring key executives in a fireside chat. The event is scheduled for April 13, 2021, and will be accessible via webcast for 90 days. This engagement underscores Amphastar's focus on communication with investors and stakeholders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Amphastar Pharmaceuticals is actively engaging in industry events.
  • The participation in the Needham Virtual Healthcare Conference highlights their commitment to transparency.
  • The webcast allows broader access to their corporate insights.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
7.1%
average across 5 past catalysts
Lead asset
epinephrine
Phase 3 · Asthma

Full Press Release Details

RANCHO CUCAMONGA, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 3:45 pm Eastern time.
This presentation will be made available webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website athttp://ir.amphastar.com. This webcast will be available for 90 days following the presentation.

About Amphastar:

Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company’s finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company’s website atwww.amphastar.com.
The Amphastar Pharmaceuticals’ logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene®, Amphadase®and Cortrosyn®, are the property of Amphastar Pharmaceuticals, Inc.

Forward Looking Statements

All statements in this press release that are not historical are forward-looking statements. These statements are not historical facts but rather are based on Amphastar’s historical performance and its current expectations, estimates, and projections regarding Amphastar’s business, operations, and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission, including in the Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 15, 2021. You can locate these reports through the Company’s website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause Amphastar’s expectations to change.
Contact:
Bill PetersChief Financial Officer(909) 476-3416

Frequently Asked Questions

When is Amphastar's presentation at the Needham Conference?

Amphastar's presentation is scheduled for April 13, 2021, at 3:45 pm Eastern time.

Who will participate in the Amphastar fireside chat?

Key executives including Bill Peters, Dan Dischner, Tony Marrs, and Jacob Liawatidewi will participate.

How can I access the Amphastar conference presentation?

The presentation will be available via webcast on Amphastar's website for 90 days.

What is Amphastar Pharmaceuticals focused on?

Amphastar specializes in developing and selling generic and proprietary injectable products.

Last updated: Apr 6, 2021